Clinical Trial Update: An Open-label Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of SKP-0141 for the Treatment and Prophylaxis in Severe Hemophilia a Patients [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating SKP-0141 for treatment and prophylaxis in severe Hemophilia A, assessing efficacy, safety, pharmacokinetics, and immunogenic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• SKP-0141

Snippet

Sponsor: SK Plasma Co., Ltd. | Conditions: Hemophilia A, Severe | Phase 3 | Status: NOT_YET_RECRUITING